Clene Inc. (CLNN)

Market Cap	26.24M
Revenue (ttm)	342,000
Net Income (ttm)	-39.40M
Shares Out	8.63M
EPS (ttm)	-5.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,092
Open	2.960
Previous Close	3.030
Day's Range	2.960 - 3.130
52-Week Range	2.570 - 9.200
Beta	0.46
Analysts	Strong Buy
Price Target	50.20 (+1,551.32%)
Earnings Date	May 7, 2025

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 ...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2012
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: CLNN
• Website: https://clene.com

Financial Performance

In 2024, Clene's revenue was $342,000, a decrease of -47.71% compared to the previous year's $654,000. Losses were -$39.40 million, -20.41% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price forecast is $50.2, which is an increase of 1,551.32% from the latest price.

Price Target

$50.2

(1,551.32% upside)

Analyst Consensus: Strong Buy